Kapoose Creek Bio, a biotechnology company leveraging AI for drug discovery from nature, has acquired an exclusive license to Adapsyn Bioscience’s chemical informatics platform, and acquired its drug discovery lab and talent.
 
The agreement with Adapsyn, a Canadian company backed by Genesys Capital and other private investors, offers Kapoose Creek Bio an opportunity to accelerate its growth, and further populate its development pipeline.
 
Adapsyn’s informatics technologies complement Kapoose Creek Bio’s unEarth Rx platform, a suite of AI-powered tools that dramatically accelerates the discovery of drugs from nature, yielding high-quality leads for crucial new medicines. Together, the platforms create an end-to-end bespoke solution for natural product drug discovery, able to address the biggest challenges in the field – providing new capabilities to explore nature’s chemistry, characterizing its potential as medicine, and producing natural products and their derivatives at scale – at unprecedented speed.
 
“This acquisition promises substantial short- and long-term benefits, and we’re extremely excited about what it means for our future,” said Dr. Eric Brown, CEO, Kapoose Creek Bio.  “Having exclusive access to proprietary technology that complements our own will significantly accelerate our efforts to further populate our pipeline and increase our value proposition.”
 
“We are delighted that Adapsyn’s AI platform will be further leveraged at Kapoose Creek Bio,” said Kelly Holman, Managing Director, Genesys Capital. “The company is well positioned to forge new ground in drug discovery.”
 
In addition to the licensing of Adapsyn’s technology, Kapoose Creek Bio will acquire rights to its proprietary collection of microbes and novel natural products, along with Adapsyn’s fully equipped natural product drug discovery chemistry laboratory at McMaster Innovation Park (MIP) in Ontario. An interdisciplinary team of four scientists from Adapsyn will also join Kapoose Creek Bio, with expertise that spans chemistry, microbiology and computation. All are globally recognized talents who have worked with the technology since its inception and are responsible for creating the platform.  
 
“We are thrilled to welcome our new talent and build on the remarkable progress we have achieved to date,” added Dr. Brown. “With exclusive access to world-leading technology and talent, a growing collection of drug-like chemistry from nature, and two lead compounds already identified, we are well on our way to propelling the development of groundbreaking therapies from nature.”

Other Pharma Industry Acquisitions